Literature DB >> 18782680

Intermittent preventive antimalarial treatment to children (IPTc): firebreak or fire trap?

Pierre A Buffet1, Valérie Briand, Laurent Rénia, Marc Thellier, Martin Danis, Dominique Mazier.   

Abstract

Intermittent preventive treatment is the prescheduled administration of antimalarial drugs to at-risk patients in endemic areas. This approach, which is recommended for pregnant women, is being evaluated in children. Sulfadoxine-pyrimethamine plus amodiaquine recently proved to be more protective than artemisinin-containing regimens. Therefore, the use of artemisinin derivatives could potentially be restricted to symptomatic patients. Determinants of three pending issues: safety, efficacy throughout childhood, and effectiveness--the latter depending on the implementation of sustainable delivery mechanisms--are analyzed in this comment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18782680     DOI: 10.1016/j.pt.2008.07.007

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  6 in total

1.  Sulfadoxine-pyrimethamine impairs Plasmodium falciparum gametocyte infectivity and Anopheles mosquito survival.

Authors:  Aminatou Kone; Marga van de Vegte-Bolmer; Rianne Siebelink-Stoter; Geert-Jan van Gemert; Antoine Dara; Hamidou Niangaly; Adrian Luty; Ogobara K Doumbo; Robert Sauerwein; Abdoulaye A Djimde
Journal:  Int J Parasitol       Date:  2010-06-02       Impact factor: 3.981

2.  Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trial.

Authors:  Alassane Dicko; Abdoulbaki I Diallo; Intimbeye Tembine; Yahia Dicko; Niawanlou Dara; Youssoufa Sidibe; Gaoussou Santara; Halimatou Diawara; Toumani Conaré; Abdoulaye Djimde; Daniel Chandramohan; Simon Cousens; Paul J Milligan; Diadier A Diallo; Ogobara K Doumbo; Brian Greenwood
Journal:  PLoS Med       Date:  2011-02-01       Impact factor: 11.069

3.  Determinants of the cost-effectiveness of intermittent preventive treatment for malaria in infants and children.

Authors:  Amanda Ross; Nicolas Maire; Elisa Sicuri; Thomas Smith; Lesong Conteh
Journal:  PLoS One       Date:  2011-04-07       Impact factor: 3.240

4.  Immunological consequences of intermittent preventive treatment against malaria in Senegalese preschool children.

Authors:  Denis Boulanger; Jean Biram Sarr; Florie Fillol; Cheikh Sokhna; Badara Cisse; Anne-Marie Schacht; Jean-François Trape; Gilles Riveau; François Simondon; Brian Greenwood; Franck Remoué
Journal:  Malar J       Date:  2010-12-17       Impact factor: 2.979

5.  Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children.

Authors:  Badara Cisse; Matthew Cairns; Ernest Faye; Ousmane NDiaye; Babacar Faye; Cecile Cames; Yue Cheng; Maguette NDiaye; Aminata Collé Lô; Kirsten Simondon; Jean-Francois Trape; Oumar Faye; Jean Louis NDiaye; Oumar Gaye; Brian Greenwood; Paul Milligan
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

6.  Impact Evaluation of Seasonal Malaria Chemoprevention under Routine Program Implementation: A Quasi-Experimental Study in Burkina Faso.

Authors:  Thomas Druetz; Nicolas Corneau-Tremblay; Tieba Millogo; Seni Kouanda; Antarou Ly; Abel Bicaba; Slim Haddad
Journal:  Am J Trop Med Hyg       Date:  2017-12-14       Impact factor: 2.345

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.